CJC-1295 vs Tesamorelin: GHRH Analog Comparison & Half-Life
CJC-1295 and Tesamorelin are both GHRH receptor agonists — but the half-life, clinical data, and pharmacokinetic profiles diverge sharply.
CJC-1295 and Tesamorelin are both synthetic GHRH analogs — they bind the same receptor and stimulate the same downstream GH release. The differences are in stability, half-life, and clinical evidence base.
Same receptor, different stability strategies
Both peptides bind the GHRH receptor (GHRHR) on pituitary somatotropes and drive pulsatile GH release through the same cAMP-mediated pathway. The molecular difference is how each one resists degradation.
Tesamorelin uses an N-terminal trans-3-hexenoyl modification on the full GHRH(1-44) sequence to block DPP-IV. CJC-1295 uses four amino-acid substitutions on the GHRH(1-29) fragment — and the DAC variant adds a maleimide group that covalently binds serum albumin to extend half-life to ~8 days.
The half-life decision
CJC-1295 without DAC and Tesamorelin have similar plasma half-lives in the 30-minute range, preserving pulsatile GH release. CJC-1295 with DAC produces tonic (not pulsatile) GH elevation lasting roughly a week per dose — a fundamentally different research profile.
Clinical evidence base
Tesamorelin is the only GHRH analog with full FDA approval, backed by Phase-3 trials showing ~15–18% reductions in visceral adipose tissue (VAT) over 26 weeks in HIV-associated lipodystrophy patients.
CJC-1295 has only published PK/PD data and is not FDA-approved for any indication.
Research verdict
Tesamorelin is the better-validated choice for studies requiring published human efficacy data — particularly anything related to visceral adipose tissue. CJC-1295 (typically the no-DAC version paired with Ipamorelin) is the more common pick in protocols that prioritize pulsatile GH release and pair a GHRH with a GHRP for synergy.
Literature notice
Any clinical trial figures referenced on this page describe published studies of approved, physician-supervised pharmaceutical drug products. They are cited for scientific literature context only. They are not results, claims, or representations about the research materials sold by Redline Bio Labs. All materials sold are supplied strictly for in-vitro laboratory research use only, are not drugs, and are not for human or veterinary consumption or administration of any kind.
Frequently asked questions
Is CJC-1295 or Tesamorelin stronger?
Per microgram, both are full GHRH receptor agonists with similar in-vitro potency. Tesamorelin has more published clinical data; CJC-1295 with DAC has a much longer half-life but produces tonic rather than pulsatile GH release.
Why pair CJC-1295 with Ipamorelin but not Tesamorelin?
Researchers do pair Tesamorelin with GHRPs in some protocols. The CJC-1295 + Ipamorelin pairing is simply more common because both are widely available as research peptides and the synergy data is well-documented.
Which has more clinical trial data?
Tesamorelin, by a wide margin. It is the only GHRH analog with full FDA approval (Egrifta) and Phase-3 trial data on visceral fat reduction.